PGA-timolol combo effective for POAG

Article

A combination of prostaglandin analog (PGA) and timolol 0.1 & gel reduces both IOP and fluctuations in primary-angle glaucoma patients, states a recent paper in European Journal of Ophthalmology.

A combination of prostaglandin analog (PGA) and timolol 0.1 & gel reduces both IOP and fluctuations in primary-angle glaucoma patients, states a recent paper in European Journal of Ophthalmology.

Dr Carlo Nucci et al., Ophthalmology Unit, Department of Exp. Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, administered fixed combinations of PGA-timolol in 64 eyes of 32 patients. This included 17 patients receiving a latanoprost-timolol fixed combination, 9 patients receiving a travoprost-timolol fixed combination and six who were administered bimatoprost-timolol fixed combination. The primary endpoint was the comparison between efficacy of fixed and unfixed combinations in lowering IOP and short-term IOP fluctuations.

All unfixed treatment combinations induced an IOP reduction that was significantly higher than the corresponding fixed treatment combinations. IOP diurnal fluctuations significantly decreased after unfixed combinations were administered, as well as increasing the percentage of patients with daily IOP fluctuation of 2 mm or less.

PGA and timolol was the most effective POAG treatment when administered as an unfixed combination. Once saily timolol 0.1% gel is a valuable treatment option as it reduces both IOP and daily fluctuations.

To read the journal abstract please click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.